- Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402
[作者：Lilenbaum, R; Wang, XF; Gu, L; Kirshner, J; Lerro, K; Vokes, E,期刊：Journal of clinical oncology, 页码：4487-4491 , 文章类型： Proceedings Paper，,卷期：2009年27-27]
- Purpose A randomized phase II trial of two novel treatment strategies in the first-line management of advanced non-small-cell lung cancer patients with performance status (PS) 2. Patients and Methods Patients were assign...
- Vasomotor Symptoms, Adoption of a Low-Fat Dietary Pattern, and Risk of Invasive Breast Cancer: A Secondary Analysis of the Women's Health Initiative Randomized Controlled Dietary Modification Trial
[作者：Caan, BJ; Aragaki, A; Thomson, CA; Stefanick, ML; Chlebowski, R; Hubbell, FA; Tinker, L; Vitolins, M; Rajkovic, A; Bueche, M; Ockene, J,期刊：Journal of clinical oncology, 页码：4500-4507 , 文章类型： Article，,卷期：2009年27-27]
- Purpose To assess whether the effect of a low-fat dietary pattern on breast cancer incidence varied by report of baseline vasomotor symptoms. Methods Postmenopausal women age 50 to 79 years enrolled onto the Women's Heal...
- Referral, Receipt, and Completion of Chemotherapy in Patients With Early-Stage Breast Cancer Older Than 65 Years and at High Risk of Breast Cancer Recurrence
[作者：Buist, DSM; Chubak, J; Prout, M; Yood, MU; Bosco, JLF; Thwin, SS; Gold, HT; Owusu, C; Field, TS; Quinn, VP; Wei, FF; Silliman, RA,期刊：Journal of clinical oncology, 页码：4508-4514 , 文章类型： Article，,卷期：2009年27-27]
- Purpose Some women with early-stage breast cancer are at higher risk of recurrence and can benefit from chemotherapy. We describe patterns of referral, receipt, and completion of chemotherapy among older women at high ri...
- Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer
[作者：Huo, DZ; Ikpatt, F; Khramtsov, A; Dangou, JM; Nanda, R; Dignam, J; Zhang, BF; Grushko, T; Zhang, CL; Oluwasola, O; Malaka, D; Malami, S; Odetunde, A; Adeoye, AO; Iyare, F; Falusi, A; Perou, CM; Olopade, OI,期刊：Journal of clinical oncology, 页码：4515-4521 , 文章类型： Proceedings Paper，,卷期：2009年27-27]
- Purpose Compared with white women, black women experience a disproportionate burden of aggressive breast cancer for reasons that remain unknown and understudied. In the first study of its kind, we determined the distribu...
- Pegylated Liposomal Doxorubicin Plus Docetaxel Significantly Improves Time to Progression Without Additive Cardiotoxicity Compared With Docetaxel Monotherapy in Patients With Advanced Breast Cancer Previously Treated With Neoadjuvant-Adjuvant Anthracycline Therapy: Results From a Randomized Phase III Study
[作者：Sparano, JA; Makhson, AN; Semiglazov, VF; Tjulandin, SA; Balashova, OI; Bondarenko, IN; Bogdanova, NV; Manikhas, GM; Oliynychenko, GP; Chatikhine, VA; Zhuang, SH; Xiu, L; Yuan, ZL; Rackoff, WR,期刊：Journal of clinical oncology, 页码：4522-4529 , 文章类型： Proceedings Paper，,卷期：2009年27-27]
- Purpose To determine whether the combination of pegylated liposomal doxorubicin (PLD) and docetaxel significantly prolongs time to disease progression compared with docetaxel alone without an increase in cardiac toxicity...
- Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study
[作者：Robertson, JFR; Llombart-Cussac, A; Rolski, J; Feltl, D; Dewar, J; Macpherson, E; Lindemann, J; Ellis, MJ,期刊：Journal of clinical oncology, 页码：4530-4535 , 文章类型： Article，,卷期：2009年27-27]
- Purpose To compare the clinical activity of the pure antiestrogen fulvestrant at 500 mg/mo (double the approved dose) with the aromatase inhibitor anastrozole as first-line endocrine therapy for advanced hormone receptor...
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
[作者：Ellard, SL; Clemons, M; Gelmon, KA; Norris, B; Kennecke, H; Chia, S; Pritchard, K; Eisen, A; Vandenberg, T; Taylor, M; Sauerbrei, E; Mishaeli, M; Huntsman, D; Walsh, W; Olivo, M; McIntosh, L; Seymour, L,期刊：Journal of clinical oncology, 页码：4536-4541 , 文章类型： Proceedings Paper，,卷期：2009年27-27]
- Purpose To evaluate the safety and efficacy of oral everolimus, a mammalian target of rapamycin (mTOR) inhibitor, in two different schedules in minimally pretreated patients with metastatic breast cancer and to explore f...
- Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
[作者：Engert, A; Diehl, V; Franklin, J; Lohri, A; Dorken, B; Ludwig, WD; Koch, P; Hanel, M; Pfreundschuh, M; Wilhelm, M; Trumper, L; Aulitzky, WE; Bentz, M; Rummel, M; Sezer, O; Muller-Hermelink, HK; Hasenclever, D; Loffler, M,期刊：Journal of clinical oncology, 页码：4548-4554 , 文章类型： Article，,卷期：2009年27-27]
- Purpose The HD9 trial of the German Hodgkin Study Group compared two different doses (baseline and escalated) of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP...
- Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
[作者：Federico, M; Bellei, M; Marcheselli, L; Luminari, S; Lopez-Guillermo, A; Vitolo, U; Pro, B; Pileri, S; Pulsoni, A; Soubeyran, P; Cortelazzo, S; Martinelli, G; Martelli, M; Rigacci, L; Arcaini, L; Di Raimondo, F; Merli, F; Sabattini, E; McLaughlin, P; Solal-Celigny, P,期刊：Journal of clinical oncology, 页码：4555-4562 , 文章类型： Proceedings Paper，,卷期：2009年27-27]
- Purpose The aim of the F2 study was to verify whether a prospective collection of data would enable the development of a more accurate prognostic index for follicular lymphoma (FL) by using parameters which could not be ...
- Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
[作者：Tefferi, A; Verstovsek, S; Barosi, G; Passamonti, F; Roboz, GJ; Gisslinger, H; Paquette, RL; Cervantes, F; Rivera, CE; Deeg, HJ; Thiele, J; Kvasnicka, HM; Vardiman, JW; Zhang, YM; Bekele, BN; Mesa, RA; Gale, RP; Kantarjian, HM,期刊：Journal of clinical oncology, 页码：4563-4569 , 文章类型： Article，,卷期：2009年27-27]
- Purpose Thalidomide and lenalidomide can alleviate anemia in myelofibrosis. However, their value is undermined by their respective potential to cause peripheral neuropathy and myelosuppression. We therefore evaluated the...
- Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia
[作者：Ringden, O; Labopin, M; Ehninger, G; Niederwieser, D; Olsson, R; Basara, N; Finke, J; Schwerdtfeger, R; Eder, M; Bunjes, D; Gorin, NC; Mohty, M; Rocha, V,期刊：Journal of clinical oncology, 页码：4570-4577 , 文章类型： Article，,卷期：2009年27-27]
- Purpose Reduced intensity conditioning regimen (RIC) is increasingly used in hematopoietic stem cell transplantation (HSCT). Unrelated donor (UD) transplants have more complications. We wanted to examine if RIC is a vali...
- Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia
[作者：Bosch, F; Abrisqueta, P; Villamor, N; Terol, MJ; Gonzalez-Barca, E; Ferra, C; Diaz, MG; Abella, E; Delgado, J; Carbonell, F; Marco, JAG; Escoda, L; Ferrer, S; Monzo, E; Gonzalez, Y; Estany, C; Jarque, I; Salamero, O; Muntanola, A; Montserrat, E,期刊：Journal of clinical oncology, 页码：4578-4584 , 文章类型： Proceedings Paper，,卷期：2009年27-27]
- Purpose The addition of monoclonal antibodies to chemotherapy has significantly improved treatment of chronic lymphocytic leukemia (CLL). Based on excellent results with the chemotherapy-only regimen fludarabine, cycloph...
- Prognostic Significance of Copy-Number Alterations in Multiple Myeloma
[作者：Avet-Loiseau, H; Li, C; Magrangeas, F; Gouraud, W; Charbonnel, C; Harousseau, JL; Attal, M; Marit, G; Mathiot, C; Facon, T; Moreau, P; Anderson, KC; Campion, L; Munshi, NC; Minvielle, S,期刊：Journal of clinical oncology, 页码：4585-4590 , 文章类型： Article，,卷期：2009年27-27]
- Purpose Chromosomal aberrations are a hallmark of multiple myeloma but their global prognostic impact is largely unknown. Patients and Methods We performed a genome-wide analysis of malignant plasma cells from 192 newly ...
|